Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
Three specific tumor necrosis factor (TNF) antagonists, adalimumab, etanercept and infliximab, have been approved for the treatment of psoriasis. Their efficacy, not only in psoriasis but also in psoriatic arthritis, has been demonstrated in large prospective randomized placebo-controlled trials. At present, the discussion about the use of these drugs is dominated by issues of the risk-benefit ratio and by economic considerations. In this chapter, we give an introduction to the different TNF antagonists, with the main focus on therapy management and safety issues.
Mössner
Rotraut
R
Reich
Kristian
K
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents / Q000627:therapeutic use*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D000069285:Infliximab; D018579:Patient Selection; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept